TZP-101
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Introduction: Gastroparesis is an important clinical disorder characterised by delayed gastric emptying in the absence of…
Aliment Pharmacol Ther 2011; 33: 679–688
High-throughput screening of Tranzyme Pharma's proprietary macrocycle library using the aequorin Ca2+-bioluminescence assay…
Background Gastroparesis, a chronic disorder of abnormal gastric motility, is common in patients with diabetes mellitus. A…
PURPOSE: Ghrelin agonist TZP-101 is a potent prokinetic. This phase 2b study evaluated TZP-101 safety and efficacy in…
Background TZP‐101 is a synthetic, selective ghrelin agonist in development for gastroparesis.
AbstractBackground and objective: TZP-101 is a selective, small molecule ghrelin receptor agonist in clinical development for the…
The authors evaluate the human safety, tolerability, pharmacokinetics, and pharmacodynamics of TZP‐101, an agonist of the hGHS…
The peptide hormone ghrelin exerts a wide spectrum of activities including the stimulation of GH release, feeding, and…
Postoperative ileus (POI) is a major cause of postoperative complications and prolonged hospitalization. Ghrelin, which is the…